A SECRET WEAPON FOR MBL77

Not all individuals with CLL demand therapy. Irrespective of all latest innovations, the iwCLL still suggests watchful observation for clients with asymptomatic illness.86 This advice is predicated on not less than two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).1